Clinical trial
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously…
NCT00159757 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Terminated
Key facts
| NCT number | NCT00159757 |
|---|---|
| Title | 12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients |
| Official title | 12 Week Open Label, Multicenter, Non-Comparative Switch Study Evaluating Efficacy, Tolerability And Safety Of Oral Ziprasidone In Treatment Of Patients Suffering From Schizophrenia Who Have Already Been Treated With An Other Antipsychotic. |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | ziprazidone |
| Enrollment | 150 |
| Start date | Nov 1, 2003 |
| Completion | Feb 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Feb 21, 2021 |
| Countries | Hungary |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: